Igovomab: Difference between revisions
Jump to navigation
Jump to search
m Protected "Igovomab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 27: | Line 27: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 33: | Line 33: | ||
{{Mousemonoclonals}} | {{Mousemonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 16:17, 9 August 2012
WikiDoc Resources for Igovomab |
Articles |
---|
Most recent articles on Igovomab |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Igovomab at Clinical Trials.gov Clinical Trials on Igovomab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Igovomab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Igovomab Risk calculators and risk factors for Igovomab
|
Healthcare Provider Resources |
Causes & Risk Factors for Igovomab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Igovomab is a mouse monoclonal antibody and which it is used to treat ovarian cancer.